Asset
Palazestrant
Olema Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04505826 | phase1_2 | completed | 2020-08-13 | 2024-07-30 | Olema Pharmaceuticals, Inc. | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.